Last reviewed · How we verify
XL184
XL184 is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and RET signaling to inhibit tumor growth and angiogenesis.
XL184 is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and RET signaling to inhibit tumor growth and angiogenesis. Used for Metastatic medullary thyroid cancer, Renal cell carcinoma, Hepatocellular carcinoma.
At a glance
| Generic name | XL184 |
|---|---|
| Sponsor | Exelixis |
| Drug class | Multi-targeted tyrosine kinase inhibitor |
| Target | MET, VEGFR2, RET |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
XL184 (cabozantinib) inhibits multiple receptor tyrosine kinases including MET (hepatocyte growth factor receptor), VEGFR2 (vascular endothelial growth factor receptor 2), and RET (rearranged during transfection). By blocking these pathways, it suppresses tumor cell proliferation, survival, and the formation of new blood vessels that feed tumors. This multi-targeted approach is particularly effective in cancers driven by MET or RET alterations.
Approved indications
- Metastatic medullary thyroid cancer
- Renal cell carcinoma
- Hepatocellular carcinoma
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Decreased appetite
- Hand-foot skin reaction
- Hypertension
- Vomiting
- Weight loss
Key clinical trials
- Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (PHASE2)
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study (PHASE2)
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial (PHASE1, PHASE2)
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XL184 CI brief — competitive landscape report
- XL184 updates RSS · CI watch RSS
- Exelixis portfolio CI